Navigation Links
Radioactive 'understudy' may aid medical imaging, drug development
Date:1/9/2008

Broadway stars have understudies. Now, an increasingly popular radioactive isotope has its own stand-in. Developed in part by researchers at the National Institute of Standards and Technology (NIST), the substance might ultimately improve medical imaging, speed up clinical trials of many drugs and facilitate efforts to develop more individualized medical treatment.

The number of medical images obtained through the technique known as positron emission tomography (PET) is increasing at a rate of 20 percent a yearand this has correspondingly increased the use of fluorine-18, the radioactive isotope of choice in the vast majority of PET procedures. Injected into the bloodstream while bound to carrier molecules, fluorine-18 lights up the body during PET scans to perform such jobs as revealing tumors, monitoring heart activity and determining which regions of the brain are active during certain tasks.

However, fluorine-18 has a very short lifea batch of the stuff decays to half its initial quantity in fewer than two hours, and less than one-ten-thousandth of the original amount is left after a single day. Because the stuff decays so quickly, it is not possible for a single central lab to make precise measurements on fluorine-18 solutions and then distribute them to far-flung centers to calibrate PET machines. This lack of a standard reference for fluorine-18 means that PET-related measurements from center to center, from patient to patient, and even in the same patient over time, are difficult or impossible to compare with one another.

NIST researchers, collaborating with an Ohio-based nuclear medicine company called RadQual, have turned to germanium-68 as a calibration surrogate for fluorine-18. This germanium isotope is much longer livedits half-life is 270.95 daysbut its radiation decay characteristics are otherwise similar to fluorine-18. Small differences between measurements of germanium-68 and fluorine-18 can be accounted for through the use of mathematical conversion factors. Germanium-68 never would be used in actual PET procedures; it would only be used to calibrate the machines properly, enabling more accurate measurements of the fluorine-18 isotopes. Although germanium-68 has been used for performing corrections on PET scanners, the industry has lacked a nationally traceable standard reference material for instrument calibration.

NIST researchers have calibrated solutions of germanium-68 that could become the basis of a new standard reference material for this isotope. The next phase of this project involves working with RadQual to calibrate a new mock syringe standard that would use germanium-68 embedded in an epoxy to simulate fluorine-18 in a syringe. This would help researchers more accurately determine the amount of fluorine-18 to be injected into patients during the PET procedure so as to minimize radiation dose while still producing the best image. NIST is also working independently on a germanium-68-based PET phantom that can be used to calibrate PET scanners in a way that is traceable back to NIST.

The first commercial products from this collaboration may be reaching PET centers later this year. By giving doctors more accurate results on how specific patients are responding to cancer treatments and providing more precise indications earlier in clinical trials as to how individual patients are metabolizing particular drugs, better standards for PET imaging may hasten the arrival of individualized medicine.


'/>"/>

Contact: Ben Stein
ben.stein@nist.gov
301-975-3097
National Institute of Standards and Technology (NIST)
Source:Eurekalert

Related biology news :

1. American College of Medical Genetics responds to new FDA labeling decision for warfarin
2. M2SYS Partners With Gnosis Medical Services to Provide Accurate Patient Identification in Developing Countries Through Innovative Biometrics Solution
3. Boston University biomedical engineers find chink in bacterias armor
4. $22 million gift from Alfred Taubman launches new biomedical research institute
5. USC biomedical team to participate in $6 million low vision project
6. 3 Columbia University Medical Center faculty elected to Institute of Medicine
7. Phase 2 of Singapores Biomedical Sciences Initiative gains momentum for clinical research
8. UMass Medical School researchers receive $8.5M grant award to fight AIDS
9. Natural product discovery by Cleveland medical researchers blocks tissue destruction
10. Triage study challenges notions of emergency medical response to disaster
11. Titanium Group Signs Letter of Intent to Acquire Multimilion Dollar Medical Software Company and Its Existing Sales Network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... LONDON , Jan. 20, 2016 A ... positioned to directly benefit from the explosion in genomics ... from Howe Sound Research. A range of dynamic trends ... ...... - personalized medicine - pharmacogenomics - pathogen ... economies with large markets - greater understanding of the ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... 2016 NX Prenatal Inc., a US ... technology for early warning of adverse pregnancy outcomes, ... study by Dr. Thomas McElrath of ... Fetal Medicine,s (SMFM) annual meeting held in ... 2016.  The presentation reported initial positive top-line results ...
(Date:2/10/2016)... New York (PRWEB) , ... ... ... Inc. (NASDAQ: REGN) today announced that it has joined the Human Vaccines ... immunotherapies for infectious diseases and cancer. , The Human Vaccines Project ...
(Date:2/10/2016)... plc (NYSE: AGN ) a leading global pharmaceutical ... CEO and President, will be featured as the keynote ... Capital Markets Healthcare Conference on Tuesday, February 23, 2016 ... Hotel in New York, NY . ... accessed on Allergan,s Investor Relations web site at ...
(Date:2/10/2016)... ... 10, 2016 , ... Benchmark Research, a fully-integrated network of ... long-standing principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research ... Laurence Chu, a Benchmark Research PI in the Austin office, will assume the ...
Breaking Biology Technology: